You're Telling Us... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

You're Telling Us...
PharmTech's polls feature user feedback on issues facing the pharmaceutical industry.


Pharmaceutical Technology


Alexis Brekke
The editors at Pharmaceutical Technology worked hard last month developing ways to improve our online offerings, from the launch of a new Equipment & Processing report to a redesigned weekly enewsletter (ePT) to the creation of PharmTech Polls. This new feature on pharmtech.com is a way to give you, our readers, a voice online and allow you to weigh in on important industry topics.

So far, voters have shared their definitions of "design space," predictions for the future of inhalation drug delivery, concerns about over-the-counter (OTC) children's medications, options for reforming the US Food and Drug Administration's foreign inspections process, speculations on the industry's focus in 2008, and more.

Your feedback is often honest and insightful. One user described "design space" as "just a new buzzword for defining the acceptable range of a product and process, which is something an optimization program should have done for many years now."

In response to our question on standardizing dosing devices for OTC children's medications, which all respondents supported, one user said these medications and devices should be sold in the same manner as pseudoephedrine formulations—directly by a pharmacist.

A comment stemming from our inhalation delivery poll says "the science to deliver macromolecules for systemic absorption has been pushed too rapidly by a selected few in the 'aerosol delivery' scientific community," warning that the implications of this delivery method on the lungs are not completely understood.

We look forward to hearing more input from you. Share your views with us at pharmtech.com/polls.

Alexis Brekke is an assistant editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here